Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
23 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cold Genesys, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cold Genesys, Inc. - Product Pipeline Review - 2014', provides an overview of the Cold Genesys, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cold Genesys, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cold Genesys, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cold Genesys, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cold Genesys, Inc.'s pipeline products Reasons to buy - Evaluate Cold Genesys, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cold Genesys, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cold Genesys, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cold Genesys, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cold Genesys, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cold Genesys, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Cold Genesys, Inc. Snapshot 4 Cold Genesys, Inc. Overview 4 Key Information 4 Key Facts 4 Cold Genesys, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Cold Genesys, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Cold Genesys, Inc. - Pipeline Products Glance 9 Cold Genesys, Inc. - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Cold Genesys, Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 Cold Genesys, Inc. - Drug Profiles 12 CG-0070 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 CG-0070-IT 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CG-001-EV 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Cold Genesys, Inc. - Pipeline Analysis 16 Cold Genesys, Inc. - Pipeline Products by Target 16 Cold Genesys, Inc. - Pipeline Products by Route of Administration 17 Cold Genesys, Inc. - Pipeline Products by Molecule Type 18 Cold Genesys, Inc. - Pipeline Products by Mechanism of Action 19 Cold Genesys, Inc. - Recent Pipeline Updates 20 Cold Genesys, Inc. - Locations And Subsidiaries 21 Head Office 21 Appendix 22 Methodology 22 Coverage 22 Secondary Research 22 Primary Research 22 Expert Panel Validation 22 Contact Us 23 Disclaimer 23
List of Tables Cold Genesys, Inc., Key Information 4 Cold Genesys, Inc., Key Facts 4 Cold Genesys, Inc. - Pipeline by Indication, 2014 6 Cold Genesys, Inc. - Pipeline by Stage of Development, 2014 7 Cold Genesys, Inc. - Monotherapy Products in Pipeline, 2014 8 Cold Genesys, Inc. - Phase II, 2014 9 Cold Genesys, Inc. - Preclinical, 2014 10 Cold Genesys, Inc. - Discovery, 2014 11 Cold Genesys, Inc. - Pipeline by Target, 2014 16 Cold Genesys, Inc. - Pipeline by Route of Administration, 2014 17 Cold Genesys, Inc. - Pipeline by Molecule Type, 2014 18 Cold Genesys, Inc. - Pipeline Products by Mechanism of Action, 2014 19 Cold Genesys, Inc. - Recent Pipeline Updates, 2014 20
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.